Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Section 4 of 6

Clinical evidence

288 evidence topics · 46 sources

Study summaries

upLIFT

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using glucose infusion rate reduction of at least 50% as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Design: upLIFT is a single-arm, open-label trial of 16 participants with no concurrent comparator, so the responder proportion is judged against a prespecified threshold (lower bound of the 95% confidence interval above 30%). The source documents word the threshold as “must exceed 30%” and as “must be ≥30%”.
  • Status of the data: the results are preliminary and come from company press releases and SEC filings; no publication, congress presentation, or registry results exist. At the 13 November 2026 evaluation, 3 participants remained in the pivotal period, and the final responder proportion and its confidence interval may differ.
  • Applicability: participants are adults who require IV glucose or parenteral nutrition despite standard-of-care therapies, with the primary endpoint measured in a hospital setting, and receive ersodetug as an add-on; the results describe the most severe presentation. Results by tumor type (insulinoma or non-islet cell tumor) and patient-reported quality of life have not been reported.
  • One participant with stage 4 metastatic colon cancer withdrew to hospice and was counted as a non-responder; outcomes in participants with poor performance status are therefore represented by a single case.
  • Registry records lag the company: ClinicalTrials.gov still lists the trial as recruiting, while the company reports enrollment complete.

Expanded access program in Tumor hyperinsulinism

Objective
Location and study date
Status, dates, and location of the intermediate-size cohort expanded access program
FieldQuoted record
Expanded access status“Available”
Other study ID number“RZ358-303”
First submitted“2025-11-21”
First posted“2025-12-04”
Last update posted“2026-10-07”
Location“New Orleans, Louisiana, United States, 70112”
Study design
Eligibility criteria
Age and sex eligibility of the intermediate-size cohort expanded access program
FieldQuoted record
Ages eligible“18 Years and older”
Sexes eligible“All”
Treatment
Dose regimen by patient in the company table of 9 patients
Intervention in the intermediate-size cohort expanded access program
Study outcomes
Rationale for using discontinuation of parenteral glucose as the primary outcome
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Treatment duration and survival by patient in the company table of 9 patients
PatientTotal duration of ersodetug therapy (months)Overall survival (months)
Patient 1“13”“14”
Patient 2“5”“5”
Patient 3“5”“5”
Patient 4“14”“14”
Patient 5“22 (ongoing)”“22 (living)”
Patient 6“18 (ongoing)”“18 (living)”
Patient 7“6”“6”
Patient 8“1.5”“1.5”
Patient 9“10”“10”
Baseline characteristics
Demographics, tumor, and organ function by patient in the peer-reviewed case series
CharacteristicPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
Gender; age (years)“M; 55”View highlighted excerpt for this quote“F; 50”View highlighted excerpt for this quote“F; 50”View highlighted excerpt for this quote“F; 43”View highlighted excerpt for this quote“M; 74”View highlighted excerpt for this quote“M; 62”View highlighted excerpt for this quote“F; 74”View highlighted excerpt for this quote“M; 24”View highlighted excerpt for this quote
Country“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“The Netherlands”View highlighted excerpt for this quote
Race/ethnicity“White, Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote
Diagnosis“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Neuroendocrine Carcinoma of the Cervix”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote
Diagnosis year“2021”View highlighted excerpt for this quote“2015”View highlighted excerpt for this quote“2022”View highlighted excerpt for this quote“2021”View highlighted excerpt for this quote“2023”View highlighted excerpt for this quote“2019”View highlighted excerpt for this quote“2022”View highlighted excerpt for this quote“2022”View highlighted excerpt for this quote
Tumor primary site“Pancreas”View highlighted excerpt for this quote“Pancreas”View highlighted excerpt for this quote“Cervix (neuroendocrine carcinoma)”View highlighted excerpt for this quote“Pancreas”View highlighted excerpt for this quote“Pancreas (primary pancreatic NET with liver metastases)”View highlighted excerpt for this quote“Pancreas (well-differentiated pancreatic NET)”View highlighted excerpt for this quote“Pancreas (well-differentiated NET in pancreatic body)”View highlighted excerpt for this quote“Pancreas (primary insulinoma diagnosed 2022; right-sided hemihepatectomy in 2024 at time of insulinoma)”View highlighted excerpt for this quote
Ki-67 (% and biopsy site)“8% (liver metastasis biopsy)”View highlighted excerpt for this quote“17.6% (liver resection specimen); primary pancreatic tumor Ki-67 9%”View highlighted excerpt for this quote“75% (liver metastasis biopsy)”View highlighted excerpt for this quote“5% (pancreatic primary tumor)”View highlighted excerpt for this quote“35% (liver metastasis; secondary tumor)”View highlighted excerpt for this quote“Unknown (fine-needle aspiration showing well-differentiated pancreatic NET)”View highlighted excerpt for this quote“42% (liver core needle biopsy; WHO grade 3 well-differentiated NET)”View highlighted excerpt for this quote“16% (pancreatic primary); 17.8% (liver metastasis)”View highlighted excerpt for this quote
Metastatic sites and burden“Multiple abdominal and multilobar hepatic lesions, abdominal pain”View highlighted excerpt for this quote“Liver, gastrohepatic lymph nodes, osseous metastases”View highlighted excerpt for this quote“Extensive metastatic burden (Multilobar liver and pelvic metastases)”View highlighted excerpt for this quote“Extesive metastatic burden (Liver, lymph nodes, bone)”View highlighted excerpt for this quote“Extensive liver tumor burden”View highlighted excerpt for this quote“Liver, periportal lymph nodes, para-aortic lymph nodes, low overall disease burden”View highlighted excerpt for this quote“Extensive bilobar hepatic metastatic burden; left hilar metastasis”View highlighted excerpt for this quote“Extensive liver tumor burden, involving an estimated 33% of the remaining left hemi-liver”View highlighted excerpt for this quote
Hepatic function at initiation“Mild ↑ transaminases, low albumin”View highlighted excerpt for this quote“Marked ↑ transaminases, low albumin”View highlighted excerpt for this quote“Mild ↑ in alk phos, low albumin”View highlighted excerpt for this quote“Marked ↑ alk phos, low albumin”View highlighted excerpt for this quote“Mild ↑ alk phos, low albumin”View highlighted excerpt for this quote“Modest ↑ transaminases”View highlighted excerpt for this quote“Moderate ↑ alk phos”View highlighted excerpt for this quote“Mild ↑ transaminases, and alk phos”View highlighted excerpt for this quote
ALT, AST (U/L)“81, 38”View highlighted excerpt for this quote“148, 144”View highlighted excerpt for this quote“22. 17”View highlighted excerpt for this quote“20, 53”View highlighted excerpt for this quote“36, 26”View highlighted excerpt for this quote“87, 75”View highlighted excerpt for this quote“44, 20”View highlighted excerpt for this quote“40, 44”View highlighted excerpt for this quote
Alkaline phosphatase (U/L)“105”View highlighted excerpt for this quote“620”View highlighted excerpt for this quote“173”View highlighted excerpt for this quote“677”View highlighted excerpt for this quote“108”View highlighted excerpt for this quote“104”View highlighted excerpt for this quote“255”View highlighted excerpt for this quote“161”View highlighted excerpt for this quote
Albumin (g/dL)“3.4”View highlighted excerpt for this quote“3.1”View highlighted excerpt for this quote“3.4”View highlighted excerpt for this quote“3.1”View highlighted excerpt for this quote“3.1”View highlighted excerpt for this quote“3.9”View highlighted excerpt for this quote“3.8”View highlighted excerpt for this quote“3.8”View highlighted excerpt for this quote
PT (sec)“NA”View highlighted excerpt for this quote“16.9”View highlighted excerpt for this quote“18.4”View highlighted excerpt for this quote“12”View highlighted excerpt for this quote“11.3”View highlighted excerpt for this quote“11.5”View highlighted excerpt for this quote“13.9”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
INR (ratio)“1.1”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“1.0”View highlighted excerpt for this quote“1.0”View highlighted excerpt for this quote“1.2”View highlighted excerpt for this quote“1.1”View highlighted excerpt for this quote
Renal function at initiation“Normal”View highlighted excerpt for this quote“Normal”View highlighted excerpt for this quote“Impaired”View highlighted excerpt for this quote“Mildly impaired”View highlighted excerpt for this quote“Normal”View highlighted excerpt for this quote“Normal”View highlighted excerpt for this quote“Normal”View highlighted excerpt for this quote“Mildly impaired”View highlighted excerpt for this quote
Creatinine (mg/dL)“1.2”View highlighted excerpt for this quote“0.8”View highlighted excerpt for this quote“2.13”View highlighted excerpt for this quote“1.26”View highlighted excerpt for this quote“1.1”View highlighted excerpt for this quote“0.9”View highlighted excerpt for this quote“0.63”View highlighted excerpt for this quote“1.3”View highlighted excerpt for this quote
eGFR (mL/min/1.73 m2)“NA”View highlighted excerpt for this quote“90”View highlighted excerpt for this quote“49”View highlighted excerpt for this quote“54”View highlighted excerpt for this quote“>60”View highlighted excerpt for this quote“>60”View highlighted excerpt for this quote“93”View highlighted excerpt for this quote“73”View highlighted excerpt for this quote
Hospitalization, performance status, and prior antihypoglycemic therapy by patient in the peer-reviewed case series
CharacteristicPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
Length of hospitalization before ersodetug (days)“28”View highlighted excerpt for this quote“NA (ambulatory)”View highlighted excerpt for this quote“15”View highlighted excerpt for this quote“49”View highlighted excerpt for this quote“34”View highlighted excerpt for this quote“NA (ambulatory)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote
Hospice planning before ersodetug“Y”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“Y”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote
Baseline ECOG“3”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Number of therapies for hypoglycemia (medications and IV glucose) before ersodetug“4”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Diazoxide“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote
Short-acting somatostatin analog (octreotide or pasireotide)“Previously Tried”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote
Long-acting somatostatin analog (lanreotide)“−”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
mTOR inhibitor (everolimus)“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
Corticosteroid (dexamethasone, prednisone)“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
GIR at ersodetug initiation (mg/kg/min)“6.0”View highlighted excerpt for this quote“7.0”View highlighted excerpt for this quote“5.1”View highlighted excerpt for this quote“6.2”View highlighted excerpt for this quote“4.9”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“5.6”View highlighted excerpt for this quote“3.1”View highlighted excerpt for this quote
Baseline characteristics by patient in the company table of 9 patients
Efficacy results
Time to discontinuation of each antihypoglycemic therapy by patient (days unless stated)
TherapyPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
IV glucose“74 (slow taper)”View highlighted excerpt for this quote“139 (50% reduction)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“42”View highlighted excerpt for this quote
Diazoxide“111”View highlighted excerpt for this quote“10”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“21”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote
Short-acting somatostatin analog (octreotide or pasireotide)“NA”View highlighted excerpt for this quote“18”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
Long-acting somatostatin analog (lanreotide)“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“30”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
mTOR inhibitor (everolimus)“∼6 months”View highlighted excerpt for this quote“18”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
Corticosteroid (dexamethasone, prednisone)“∼7 months”View highlighted excerpt for this quote“∼4 months”View highlighted excerpt for this quote“4 days”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
Hospital discharge, tumor-directed therapy, performance status, and survival by patient
OutcomePatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
Time to discharge from hospital (days)“84”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“15”View highlighted excerpt for this quote“9”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“9”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Hospitalization days in month after initiation“30”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Chemotherapy within 8 weeks (yes/no; therapy)“Y; LuTate”View highlighted excerpt for this quote“Y; FOLFOX”View highlighted excerpt for this quote“Y; Pembrolizumab”View highlighted excerpt for this quote“Y; CAPTEM”View highlighted excerpt for this quote“Y; LuTate”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Y; FOLFOX”View highlighted excerpt for this quote“Y; CAPTEM”View highlighted excerpt for this quote
Surgery within 8 weeks (yes/no; procedure)“N”View highlighted excerpt for this quote“Y; Whipple Surgery and Left Hepatectomy”View highlighted excerpt for this quote“Y; Total hysterectomy and bilateral oophorectomy”View highlighted excerpt for this quote“Y; Partial Pancreatectomy”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“Y; Hemi-hepatectomy”View highlighted excerpt for this quote
Other medical procedure within 8 weeks (yes/no; type)“N”View highlighted excerpt for this quote“Y; HACE”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“Y; HAE”View highlighted excerpt for this quote“Y; HAE”View highlighted excerpt for this quote“Y; HAE”View highlighted excerpt for this quote“Y; HAE”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
ECOG at 3 months“0”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Overall survival“14 months”View highlighted excerpt for this quote“5 months”View highlighted excerpt for this quote“5 months”View highlighted excerpt for this quote“14 months”View highlighted excerpt for this quote“17 months (living)”View highlighted excerpt for this quote“14 months (living)”View highlighted excerpt for this quote“6 months”View highlighted excerpt for this quote“10 months”View highlighted excerpt for this quote
Cause of death“Tumor progression”View highlighted excerpt for this quote“Tumor progression”View highlighted excerpt for this quote“Tumor progression”View highlighted excerpt for this quote“Tumor progression”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“MDS Progression/Sepsis”View highlighted excerpt for this quote“Tumor Progression”View highlighted excerpt for this quote
Continuous glucose monitoring parameters over 24 hours, by day, and by night
Period and parameterBaseline, 90 days before initiation: mean (min, max)Evaluable period, 90 days after initiation: mean (min, max)Relative change from baseline (%)Median change from baseline (90% CI)P value
24 hours: mean sensor glucose (mg/dL)“117.0 (86.9, 157.6)”View highlighted excerpt for this quote“138.0 (94.3, 189.5)”View highlighted excerpt for this quote“18.0”View highlighted excerpt for this quote“21.6 (6.5, 36.1)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
24 hours: time above 180 (%)“10.1 (0.6, 29.3)”View highlighted excerpt for this quote“22.7 (0.2, 56.1)”View highlighted excerpt for this quote“124.4”View highlighted excerpt for this quote“13.5 (2.9, 24.3)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
24 hours: time between 70 and 180 (%)“77.4 (61.0, 95.0)”View highlighted excerpt for this quote“69.2 (43.9, 87.3)”View highlighted excerpt for this quote“−10.6”View highlighted excerpt for this quote“−8.2 (−20.2, 4.8)”View highlighted excerpt for this quote“0.08”View highlighted excerpt for this quote
24 hours: time below 70 (%)“12.4 (1.7, 25.9)”View highlighted excerpt for this quote“8.0 (0.0, 22.4)”View highlighted excerpt for this quote“−35.6”View highlighted excerpt for this quote“−3.8 (−8.2, −1.1)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
24 hours: time below 54 (%)“2.6 (0.0, 5.2)”View highlighted excerpt for this quote“1.9 (0.0, 6.8)”View highlighted excerpt for this quote“−29.2”View highlighted excerpt for this quote“−0.5 (−2.9, 1.3)”View highlighted excerpt for this quote“0.38”View highlighted excerpt for this quote
Day (06:00 to 00:00): mean sensor glucose (mg/dL)“117.2 (86.9, 155.7)”View highlighted excerpt for this quote“139.5 (99.0, 191.2)”View highlighted excerpt for this quote“19.0”View highlighted excerpt for this quote“21.8 (9.5, 36.9)”View highlighted excerpt for this quote“0.008”View highlighted excerpt for this quote
Day: time above 180 (%)“10.4 (0.7, 31.7)”View highlighted excerpt for this quote“23.2 (0.3, 57.7)”View highlighted excerpt for this quote“123.0”View highlighted excerpt for this quote“12.9 (3.8, 23.7)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
Day: time between 70 and 180 (%)“76.8 (58.2, 95.0)”View highlighted excerpt for this quote“69.4 (42.3, 92.6)”View highlighted excerpt for this quote“−9.6”View highlighted excerpt for this quote“−6.2 (−19.7, 7.4)”View highlighted excerpt for this quote“0.25”View highlighted excerpt for this quote
Day: time below 70 (%)“12.8 (0.8, 27.5)”View highlighted excerpt for this quote“7.3 (0.0, 22.3)”View highlighted excerpt for this quote“−42.6”View highlighted excerpt for this quote“−4.6 (−11.6, −0.7)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
Day: time below 54 (%)“2.7 (0.0, 4.5)”View highlighted excerpt for this quote“2.0 (0.0, 7.2)”View highlighted excerpt for this quote“−26.8”View highlighted excerpt for this quote“−0.7 (−2.8, 1.4)”View highlighted excerpt for this quote“0.46”View highlighted excerpt for this quote
Night (00:00 to 06:00): mean sensor glucose (mg/dL)“116.4 (87.0, 163.3)”View highlighted excerpt for this quote“134.2 (80.3, 196.6)”View highlighted excerpt for this quote“15.2”View highlighted excerpt for this quote“15.6 (−3.1, 43.2)”View highlighted excerpt for this quote“0.11”View highlighted excerpt for this quote
Night: time above 180 (%)“9.3 (0.0, 26.4)”View highlighted excerpt for this quote“21.6 (0.0, 57.4)”View highlighted excerpt for this quote“132.1”View highlighted excerpt for this quote“9.3 (0.6, 26.7)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
Night: time between 70 and 180 (%)“79.3 (69.4, 95.0)”View highlighted excerpt for this quote“68.3 (42.0, 90.8)”View highlighted excerpt for this quote“−13.9”View highlighted excerpt for this quote“−7.5 (−23.9, −1.0)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
Night: time below 70 (%)“11.3 (0.8, 26.0)”View highlighted excerpt for this quote“10.0 (0.0, 28.8)”View highlighted excerpt for this quote“−11.8”View highlighted excerpt for this quote“−1.1 (−4.5, 2.6)”View highlighted excerpt for this quote“0.25”View highlighted excerpt for this quote
Night: time below 54 (%)“2.5 (0.0, 7.6)”View highlighted excerpt for this quote“1.6 (0.0, 5.4)”View highlighted excerpt for this quote“−37.1”View highlighted excerpt for this quote“−1.1 (−4.8, 2.4)”View highlighted excerpt for this quote“0.55”View highlighted excerpt for this quote
Glucose infusion rate, hospitalization, and performance status outcomes by patient in the company table of 9 patients
OutcomePatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Patient 9
Percent reduction in GIR by 8 weeks“>50%, then 100% by 9 weeks”“<50%”“100%”“100%”“100%”“n/a”“100%”“Unknown amount”“100%”
Time to IV glucose discontinuation (days)“74”“139 (achieved 50% reduction)”“4”“5”“2”“n/a”“3”“n/a”“42”
Hospitalized days in the 30 days after initiation“30”“0”“7”“8”“8”“0”“16”“30”“1”
ECOG at month 3“0”“2”“0”“0”“0”“0”“1”“5”“0”
Single published case: hypoglycemia, dextrose infusion, and discharge after ersodetug
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent serious adverse events, pooled cohort of 8
Study limitations
Summary
  • Design: the peer-reviewed report is a retrospective case series of 8 individuals treated under single-patient compassionate use, with no control group. The authors used nominal P-values without formal or prespecified hypothesis testing, could not construct 95% intervals, and developed the statistical analysis plan after the primary analyses.
  • Confounding: within 8 weeks of starting ersodetug, 7 individuals received chemotherapy, 4 had surgery, and 5 had other procedures such as hepatic arterial embolization, which can also reduce hypoglycemia. Doses and schedules changed during the program, and the first 2 individuals were treated under an earlier framework at a lower weekly dose.
  • Inconsistent counts and data: the number of patients differs by source (5 in the NANETS 2024 poster, 8 in the publication, 9 in the company table and ENDO 2026 poster). The company table and the publication differ in a patient's sex (“F; 74” and “M / 74”), and the publication gives hospitalization at entry as “median, 28 days; range, 4-66 days” in its text while its table lists a longest stay of 49 days. A company release describes the 9 patients as having malignant insulinoma and non-islet cell tumors, while the case-level tables list insulin-secreting tumors.
  • Overlap: the first patient's glucose data were previously published as a single case report, so that case is not independent evidence.
  • Safety ascertainment: disease progression was not reported as an adverse event under the program guidelines.

sunRIZE

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using weekly hypoglycemia events by self-monitored blood glucose as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Full analysis set

No evidence found.

Results
Participant disposition
Baseline characteristics
Demographics, background therapy, and baseline glycemia of the enrolled population
ParameterErsodetug 5 mg/kgErsodetug 10 mg/kgPlaceboOverall, including open-label arm
Number of participants“(N=18)”“(N=20)”“(N=17)”“(N=63)”
Age in years, mean (range)“3.4 (1-15 y)”“3.9 (5 mo to 9 y)”“4.0 (5 mo to 10 y)”“3.4 (3 mo to 15 y)”
Female, n (%)“8 (44%)”“10 (50%)”“7 (41%)”“31 (49%)”
Genetics, KATP / other or unknown, n (%)“13 (72%) / 5 (28%)”“11 (55%) / 9 (45%)”“15 (88%) / 2 (12%)”“47 (75%) / 16 (25%)”
Current standard of care therapy“17 (94%)”“18 (90%)”“17 (100%)”“60 (95%)”
Diazoxide, n (%)“9 (50%)”“11 (55%)”“5 (29%)”“26 (41%)”
Somatostatin analog, n (%)“10 (56%)”“11 (55%)”“14 (82%)”“46 (73%)”
Scheduled enteral tube feeding, n (%)“7 (39%)”“7 (35%)”“7 (41%)”“24 (38%)”
Two or more therapies, n (%)“8 (44%)”“9 (45%)”“8 (47%)”“29 (46%)”
Pancreatectomy, n (%)“2 (11%)”“3 (15%)”“2 (12%)”“8 (13%)”
Pre-study use of CGM, n (%)“8 (44%)”“11 (55%)”“9 (53%)”“32 (51%)”
Congenital HI-related hospitalizations in previous year, n (%)“6 (33%)”“12 (66%)”“10 (59%)”“32 (51%)”
Hypoglycemia events per week by SMBG, mean (range)“12.7 (5-42.0)”“13.4 (4-37)”“11.7 (3-22)”“12.6 (3-42)”
Percent time in hypoglycemia by CGM, mean (range)“23.1 (5-73)”“20.0 (6-71)”“13.0 (7-38)”“19.1 (5-73)”
HbA1c, mean % (range)“4.96 (3.9-5.9)”“5.01 (3.9-6.0)”“5.32 (4.2-6.2)”Not reported
Average glucose by SMBG, mean mg/dL“81”“82”“86”Not reported
Hypoglycemia Fear Survey worry score, mean“27.1”“28.2”“34.6”Not reported
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary
  • Population: sunRIZE enrolled participants with congenital hyperinsulinism aged 3 months to 45 years, a different disease and a younger population than adults with tumor hyperinsulinism, so its efficacy results are indirect evidence for this report. Its main relevance here is the safety data and its effect on the regulatory assessment.
  • Outcome: the trial did not meet its primary or key secondary endpoint. The favorable continuous glucose monitoring results at earlier time points and in the per protocol set are nominal, and the company's explanation of the result (self-monitored measures confounded by functional unblinding through real-time glucose monitoring) is its own interpretation.
  • Reporting: results are available only from company releases, filings, and congress slides, with no peer-reviewed publication. Sources differ on the number of discontinuations for hypersensitivity (2 serious reactions in the topline release; 3 participants in the congress slides; 4 early terminations in the January 2026 presentation), on the CGM result at 10 mg/kg (“approximate 25% reduction” against “-32%; p=0.30”), and on hypertrichosis (36% and about 35%). One baseline cell reads “12 (66%)” for 12 of 20 participants. The registry still lists an estimated enrollment of 56.
  • The open-label extension is ongoing, and its glycemic observations are described by the company as preliminary.

RIZE

Objective
Location and study date
Study dates in the trial registry
MilestoneQuoted date
Study start (actual)“2020-02-24”
Primary completion (actual)“2022-04-05”
Study completion (actual)“2022-08-19”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent time in glucose target range 70-180 mg/dL by continuous glucose monitoring as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Participant flow in the trial registry
MilestoneCohort 1, 3 mg/kgCohort 2, 6 mg/kgCohort 3, 9 mg/kgCohort 4, 3 to 9 mg/kg
Started“4”“8”“8”“3”
Completed“4”“8”“8”“3”
Not completed“0”“0”“0”“0”
Baseline characteristics
Demographics and baseline disease characteristics, intention-to-treat population
ParameterCohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 8)Cohort 4, 3 to 9 mg/kg (n = 3)Pooled (n = 23)
Age in years, mean (range)“5.8 (2–12)”“9.3 (2–22)”“5.8 (2–17)”“4.0 (2–6)”“6.7 (2–22)”
Male, n“4”“5”“3”“1”“13 (57%)”
KATP channel mutation, n“1”“5”“4”“1”“11 (48%)”
Unknown genetic etiology“3”“2”“3”“1”“9 (39%)”
Congenital HI therapy, n (%)“4”“7”“6”“3”“20 (87%)”
Diazoxide“2”“3”“1”“2”“8 (35%)”
Somatostatin analog (long acting/short acting)“2/0”“2/2”“3/3”“1/0”“8/5 (52%)”
Enteral or tube use“0”“2”“3”“0”“5 (22%)”
Pancreatectomy“0”“0”“3”“1”“4 (17%)”
History of seizure, n“4”“4”“5”“3”“16 (70%)”
Hospitalization within the past year, n“3”“3”“6”“2”“14 (61%)”
Percent time in range (70–180 mg/dL) by CGM, mean (range)“82 (74–89)”“74 (66–89)”“71 (12–90)”“68 (57–87)”“74 (12–90)”
Percent time in hypoglycemia (<70 mg/dL) by CGM, mean (range)“16 (11–22)”“22 (11–32)”“24 (6–88)”“29 (11–42)”“23 (6–88)”
Hypoglycemia events/week (<70 mg/dL) by SMBG, mean (range)“8 (1–13)”“16 (4–52)”“15 (7–29)”“8 (4–11)”“13 (1–52)”
Sex, race, and country of enrollment in the trial registry results
CharacteristicQuoted total (n = 23)
Female“13”
Male“10”
White“20”
Enrolled in Turkey“7”
Enrolled in Russia“5”
Enrolled in Bulgaria“3”
Efficacy results
Primary endpoint: percent time in range 70-180 mg/dL by CGM, per-protocol population
MeasureCohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 7)Cohort 4, 3 to 9 mg/kg (n = 3)Pooled (n = 22)
Median daily percent time in range at baseline“81.7”“72.9”“83.4”“59.3”“76.9”
Median daily percent time in range at week 8“84.8”“78.5”“82.9”“70.8”“79.1”
Median percent change from baseline“6.19”“0.31”“5.52”“9.07”“4.59”
Key secondary endpoints: hypoglycemia events by SMBG and time in hypoglycemia by CGM, per-protocol population
MetricCohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 7)Cohort 4, 3 to 9 mg/kg (n = 3)Pooled, median (range)
Hypoglycemia events (<70 mg/dL) by BGM, events/week, baseline“10.1”“12.5”“13.0”“9.3”“11.5 (4.0–52.0)”
Hypoglycemia events (<70 mg/dL) by BGM, events/week, end of treatment“9.9”“6.6”“1.9”“7.6”“5.0 (0–23.8)”
Hypoglycemia events (<70 mg/dL), % change from baseline (p value)“−1.6 (NS)”“−48 (0.016)”“−84 (0.016)”“−19.9 (NS)”“−59 (<0.001)”
Severe hypoglycemia events (<50 mg/dL), % change from baseline (p value)“−40 (NS)”“−78 (NS)”“−100 (0.016)”“−27 (NS)”“−78 (0.005)”
Time in hypoglycemia (<70 mg/dL) by CGM, %, baseline“16.3”“20.3”“13.7”“34.4”“16.2 (6–88)”
Time in hypoglycemia (<70 mg/dL) by CGM, %, end of treatment“12.3”“6.7”“5.4”“20.4”“8.5 (0.3–34)”
Time in hypoglycemia (<70 mg/dL), % change from baseline (p value)“−31 (NS)”“−65 (0.023)”“−61 (0.016)”“−47 (NS)”“−54 (<0.001)”
Time in severe hypoglycemia (<50 mg/dL), % change from baseline (p value)“−22 (NS)”“−74 (NS)”“−85 (NS)”“−61 (NS)”“−65 (NS)”
Overnight hypoglycemia and time above range, per-protocol population
EndpointCohort 1, 3 mg/kgCohort 2, 6 mg/kgCohort 3, 9 mg/kgCohort 4, 3 to 9 mg/kgPooled
Overnight (8 h) percent time <70 mg/dL by CGM, % change (p value)“−15.8 (NS)”“−54.8 (NS)”“−55.0 (NS)”“−61.9 (NS)”“−52.2 (0.006)”
Overnight (8 h) event rate <70 mg/dL by CGM, % change (p value)“−15.5 (NS)”“−49.3 (NS)”“−42.9 (NS)”“−56.5 (NS)”“−40.7 (0.04)”
Percent time above range (>180 mg/dL) by CGM, net change“+0.53”“+6.7”“+9.4”“+10.4”“+6.03”
Average overnight glucose (mg/dL) by CGM, net change“−2.5”“+21.5”“+19.3”“+19.8”“+17.8”
Fasting challenge in the trial registry
MeasureCohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 7)Cohort 4, 3 to 9 mg/kg (n = 3)Pooled (n = 22)
Participants able to complete fast at baseline“3”“2”“0”“0”“5”
Participants able to complete fast at end of treatment“3”“1”“2”“1”“7”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Overview of treatment-emergent adverse events, safety population
CategoryPre-treatment non-TEAE, total (n = 23)Cohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 8)Cohort 4, titrate (n = 3)Ersodetug, total (n = 23)
Participants with adverse events, n (%)“10 (43)”“2 (50)”“7 (88)”“5 (63)”“2 (67)”“16 (70)”
Participants with serious adverse events, n (%)“0 (0)”“0 (0)”“2 (25)”“1 (13)”“0 (0)”“3 (13)”
Participants with investigator-judged study drug-related adverse events, n (%)“2 (9)”“0 (0)”“2 (25)”“1 (13)”“0 (0)”“3 (13)”
Participants with grade 3 (severe) adverse events, n (%)“1 (4)”“0 (0)”“2 (25)”“0 (0)”“0 (0)”“2 (9)”
Participants with grade 4 (life threatening) adverse events, n (%)“0 (0)”“0 (0)”“0 (0)”“1 (13)”“0 (0)”“1 (4)”
Study limitations
Summary
  • Design: RIZE was an open-label, uncontrolled study of 23 participants with sequential dose cohorts and 8 weeks of treatment, and its sample size was not powered for the primary or key secondary endpoints.
  • Population: participants had congenital hyperinsulinism and were 2 years of age or older, so the study provides indirect evidence of efficacy for adults with tumor hyperinsulinism.
  • Outcome: the improvements in hypoglycemia did not translate into a similar improvement in time in range, the registry primary endpoint. The registry reports this endpoint as medians in the per protocol population, while the publication reports means in the intention-to-treat population.
  • Reporting: the registry results and the publication differ on sex distribution, and the 2022 company releases describe dosing as “bi-monthly” where the publication gives “every other week (bi-weekly)”.

XOMA 358 First-in-Human study

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • The study enrolled only healthy adult males and gave single doses, so it describes pharmacokinetics, pharmacodynamics, and short-term tolerability without information on repeated dosing or on patients with hyperinsulinism.
  • Only the abstract and company releases are openly available; the full text, with eligibility, disposition, baseline characteristics, and adverse event tables, is closed access, and no registry identifier was found. The reported number of healthy volunteers differs across documents (29 in the publication; 22 across two phase 1 studies in a later publication).